MedTrace Logo

The SAFE Prospective Registry

NCT05794464 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-09-07

No results posted yet for this study

Summary

Secretoneurin (SN) is a neuropeptide from the chromogranin family that influences intracellular calcium handling. SN suppresses calcium leakage from the sarcoplasmic reticulum through the ryanodine receptor. SN is a novel biomarker that has shown the potential to predict adverse arrhythmic events.

Conditions

  • Atrial Fibrillation, Paroxysmal or Persistent

Interventions

PROCEDURE

Catheter ablation and/or electrical cardioversion

Catheter ablation and/or electrical cardio version are procedures intended to treat atrial fibrillation.

Sponsors & Collaborators

  • University Hospital Ostrava

    lead OTHER

Principal Investigators

  • Jiří Plášek, MD,PhD,FESC · University Hospital Ostrava

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2026-05-31
Completion
2026-08-31

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05794464 on ClinicalTrials.gov